James Mason
Concepts (294)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Telomere | 11 | 2002 | 10 |
Why?
| Drosophila melanogaster | 8 | 2002 | 26 |
Why?
| Hypertension | 7 | 2003 | 161 |
Why?
| Drosophila | 3 | 2004 | 32 |
Why?
| Drosophila Proteins | 3 | 2002 | 23 |
Why?
| Diabetes Mellitus | 4 | 2003 | 72 |
Why?
| Retroelements | 5 | 2003 | 11 |
Why?
| Pancreatitis | 2 | 2007 | 24 |
Why?
| Life Style | 5 | 2004 | 55 |
Why?
| Gene Silencing | 4 | 2003 | 32 |
Why?
| Heterochromatin | 3 | 2002 | 10 |
Why?
| Evidence-Based Medicine | 5 | 2002 | 125 |
Why?
| Practice Guidelines as Topic | 4 | 2004 | 174 |
Why?
| Wound Healing | 4 | 2003 | 106 |
Why?
| DNA Transposable Elements | 3 | 2002 | 23 |
Why?
| Chromosomes | 3 | 2005 | 32 |
Why?
| DNA Breaks, Double-Stranded | 1 | 2009 | 5 |
Why?
| Relaxation Therapy | 1 | 2008 | 12 |
Why?
| Hyperlipidemias | 2 | 2003 | 42 |
Why?
| Cost-Benefit Analysis | 3 | 2004 | 118 |
Why?
| Terminal Repeat Sequences | 2 | 2003 | 6 |
Why?
| Antihypertensive Agents | 2 | 2004 | 54 |
Why?
| Diabetes Mellitus, Experimental | 2 | 2003 | 36 |
Why?
| DNA-Binding Proteins | 2 | 2008 | 204 |
Why?
| Severity of Illness Index | 1 | 2010 | 358 |
Why?
| Diabetes Complications | 3 | 2003 | 49 |
Why?
| Meta-Analysis as Topic | 1 | 2006 | 30 |
Why?
| Economics, Pharmaceutical | 1 | 2006 | 7 |
Why?
| Sodium Chloride Symporter Inhibitors | 1 | 2005 | 4 |
Why?
| Euchromatin | 1 | 2005 | 1 |
Why?
| Animals | 19 | 2001 | 1031 |
Why?
| Flavoproteins | 1 | 2004 | 5 |
Why?
| Adrenergic beta-Antagonists | 1 | 2005 | 47 |
Why?
| Amino Acid Oxidoreductases | 1 | 2004 | 9 |
Why?
| Diabetic Angiopathies | 1 | 2005 | 24 |
Why?
| Lysosomes | 1 | 2004 | 38 |
Why?
| Transduction, Genetic | 2 | 2003 | 65 |
Why?
| Transcription, Genetic | 2 | 2007 | 253 |
Why?
| Leukocytes | 1 | 2004 | 94 |
Why?
| Health Care Costs | 1 | 2004 | 73 |
Why?
| Transgenes | 4 | 2003 | 56 |
Why?
| Mutation | 4 | 2002 | 340 |
Why?
| Gene Products, gag | 1 | 2002 | 14 |
Why?
| Gene Therapy | 4 | 2003 | 89 |
Why?
| Transforming Growth Factor beta | 2 | 2001 | 99 |
Why?
| Immediate-Early Proteins | 1 | 2001 | 18 |
Why?
| Collagen Type I | 1 | 2001 | 32 |
Why?
| Growth Substances | 1 | 2001 | 51 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2001 | 64 |
Why?
| Humans | 25 | 2002 | 1856 |
Why?
| Extracellular Matrix | 1 | 2001 | 79 |
Why?
| Chromosome Mapping | 3 | 2002 | 107 |
Why?
| RNA, Messenger | 2 | 2001 | 394 |
Why?
| Base Sequence | 4 | 2003 | 371 |
Why?
| Models, Genetic | 3 | 2003 | 90 |
Why?
| Chromosomal Proteins, Non-Histone | 3 | 2002 | 6 |
Why?
| Meiosis | 2 | 2004 | 15 |
Why?
| Animals, Genetically Modified | 2 | 2003 | 29 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2005 | 176 |
Why?
| Molecular Sequence Data | 3 | 2003 | 404 |
Why?
| Telephone | 2 | 2005 | 28 |
Why?
| Proto-Oncogene Proteins c-sis | 2 | 2003 | 3 |
Why?
| Specialties, Nursing | 2 | 2003 | 2 |
Why?
| Blood Pressure | 3 | 2003 | 205 |
Why?
| Blotting, Southern | 2 | 2002 | 69 |
Why?
| Ambulatory Care | 2 | 2005 | 106 |
Why?
| APACHE | 2 | 2007 | 18 |
Why?
| Trans-Activators | 2 | 2003 | 113 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2005 | 78 |
Why?
| England | 3 | 2002 | 20 |
Why?
| Governing Board | 1 | 2011 | 2 |
Why?
| Female | 11 | 2002 | 1643 |
Why?
| Transfection | 2 | 2004 | 237 |
Why?
| State Medicine | 1 | 2011 | 10 |
Why?
| Acute Disease | 2 | 2007 | 271 |
Why?
| Preventive Medicine | 1 | 2011 | 23 |
Why?
| DNA Repair | 2 | 2009 | 47 |
Why?
| Mice | 6 | 2001 | 623 |
Why?
| Cell Cycle | 2 | 2009 | 121 |
Why?
| Male | 14 | 2002 | 1553 |
Why?
| Area Under Curve | 1 | 2010 | 47 |
Why?
| Protein Structure, Tertiary | 2 | 2008 | 163 |
Why?
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2010 | 6 |
Why?
| Aged | 8 | 2003 | 988 |
Why?
| Genes, Insect | 1 | 2009 | 3 |
Why?
| Gene Expression Regulation | 2 | 2003 | 277 |
Why?
| Adult Stem Cells | 1 | 2009 | 16 |
Why?
| Bone Regeneration | 1 | 2009 | 18 |
Why?
| Delivery of Health Care | 1 | 2011 | 102 |
Why?
| Lentivirus | 2 | 2005 | 20 |
Why?
| Health Policy | 2 | 2005 | 52 |
Why?
| Glioma | 1 | 2010 | 51 |
Why?
| Species Specificity | 1 | 2009 | 186 |
Why?
| Skull | 1 | 2009 | 48 |
Why?
| Oocytes | 1 | 2009 | 45 |
Why?
| Drug Therapy, Combination | 2 | 2005 | 189 |
Why?
| Mutagenesis, Insertional | 1 | 2008 | 37 |
Why?
| Aged, 80 and over | 3 | 2005 | 599 |
Why?
| Dermis | 2 | 2003 | 6 |
Why?
| Evolution, Molecular | 1 | 2008 | 45 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2008 | 48 |
Why?
| Sequence Homology | 1 | 2007 | 12 |
Why?
| Pyruvate Kinase | 1 | 2007 | 8 |
Why?
| Chromatin | 1 | 2008 | 29 |
Why?
| Histones | 1 | 2009 | 42 |
Why?
| Middle Aged | 7 | 2003 | 1161 |
Why?
| Group Processes | 1 | 2006 | 11 |
Why?
| Arsenicals | 1 | 2006 | 7 |
Why?
| Fertility | 1 | 2006 | 32 |
Why?
| Diet, Sodium-Restricted | 1 | 2006 | 13 |
Why?
| Longevity | 1 | 2006 | 20 |
Why?
| Review Literature as Topic | 1 | 2006 | 7 |
Why?
| Quality of Life | 2 | 2006 | 188 |
Why?
| Oxides | 1 | 2006 | 21 |
Why?
| Pancreatic Neoplasms | 1 | 2007 | 46 |
Why?
| Internationality | 1 | 2006 | 28 |
Why?
| Phenotype | 1 | 2009 | 303 |
Why?
| Social Support | 2 | 2005 | 111 |
Why?
| Primary Health Care | 1 | 2011 | 151 |
Why?
| Gene Components | 1 | 2005 | 2 |
Why?
| Genomic Library | 1 | 2005 | 11 |
Why?
| Insurance, Health, Reimbursement | 1 | 2006 | 17 |
Why?
| Models, Economic | 1 | 2006 | 14 |
Why?
| Genes, sis | 1 | 2005 | 1 |
Why?
| Hydrogen-Ion Concentration | 2 | 2004 | 176 |
Why?
| Repressor Proteins | 1 | 2008 | 96 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 135 |
Why?
| Antioxidants | 1 | 2007 | 84 |
Why?
| Pigmentation | 1 | 2004 | 7 |
Why?
| Nuclear Proteins | 1 | 2009 | 139 |
Why?
| 4-Aminobenzoic Acid | 1 | 2004 | 1 |
Why?
| Amino Acids, Aromatic | 1 | 2004 | 2 |
Why?
| Benzoic Acid | 1 | 2004 | 3 |
Why?
| L-Amino Acid Oxidase | 1 | 2004 | 2 |
Why?
| Microscopy, Electron | 1 | 2005 | 178 |
Why?
| NIH 3T3 Cells | 1 | 2004 | 22 |
Why?
| Sequence Analysis, DNA | 1 | 2005 | 110 |
Why?
| Cost Allocation | 1 | 2004 | 1 |
Why?
| HMGB1 Protein | 1 | 2004 | 1 |
Why?
| Computational Biology | 1 | 2005 | 39 |
Why?
| Fractures, Bone | 1 | 2005 | 66 |
Why?
| Mice, Inbred C57BL | 3 | 2003 | 318 |
Why?
| Health Care Rationing | 1 | 2004 | 7 |
Why?
| In Situ Hybridization | 1 | 2005 | 135 |
Why?
| Gastroenterology | 1 | 2004 | 6 |
Why?
| Genetic Markers | 1 | 2004 | 78 |
Why?
| Subcellular Fractions | 1 | 2004 | 67 |
Why?
| Myelodysplastic Syndromes | 1 | 2006 | 27 |
Why?
| Osteoporosis | 1 | 2005 | 47 |
Why?
| Eye | 1 | 2004 | 37 |
Why?
| Binding, Competitive | 1 | 2004 | 109 |
Why?
| Cell Line | 1 | 2009 | 375 |
Why?
| Quality-Adjusted Life Years | 1 | 2004 | 22 |
Why?
| Patient-Centered Care | 1 | 2005 | 30 |
Why?
| Substrate Specificity | 1 | 2004 | 90 |
Why?
| DNA Primers | 1 | 2005 | 208 |
Why?
| Promoter Regions, Genetic | 1 | 2007 | 188 |
Why?
| Adult | 5 | 2005 | 1317 |
Why?
| Health Services Research | 1 | 2004 | 63 |
Why?
| Retroviridae | 1 | 2003 | 36 |
Why?
| Oxidation-Reduction | 1 | 2004 | 124 |
Why?
| Eye Color | 1 | 2003 | 1 |
Why?
| Recombination, Genetic | 1 | 2004 | 78 |
Why?
| Immunohistochemistry | 2 | 2003 | 355 |
Why?
| Periosteum | 1 | 2003 | 12 |
Why?
| Pharmacists | 1 | 2002 | 4 |
Why?
| Blood Glucose | 1 | 2005 | 99 |
Why?
| Patient Satisfaction | 1 | 2005 | 120 |
Why?
| Drug Utilization | 1 | 2002 | 32 |
Why?
| Anaphase | 1 | 2002 | 4 |
Why?
| Algorithms | 1 | 2006 | 226 |
Why?
| Metaphase | 1 | 2002 | 11 |
Why?
| Genes, Reporter | 1 | 2003 | 111 |
Why?
| Insect Proteins | 1 | 2002 | 7 |
Why?
| Models, Biological | 1 | 2008 | 410 |
Why?
| Education, Medical, Continuing | 1 | 2002 | 54 |
Why?
| Left-Right Determination Factors | 1 | 2001 | 1 |
Why?
| Connective Tissue Growth Factor | 1 | 2001 | 1 |
Why?
| Guideline Adherence | 1 | 2002 | 64 |
Why?
| Enzyme Inhibitors | 1 | 2004 | 216 |
Why?
| Genes, Dominant | 1 | 2002 | 68 |
Why?
| DNA Probes | 1 | 2002 | 61 |
Why?
| Fibrosarcoma | 1 | 2001 | 18 |
Why?
| Risk Factors | 2 | 2005 | 555 |
Why?
| Macrophages | 1 | 2004 | 148 |
Why?
| Cartilage, Articular | 1 | 2003 | 49 |
Why?
| Matrix Metalloproteinases | 1 | 2001 | 24 |
Why?
| Stem Cell Transplantation | 1 | 2003 | 50 |
Why?
| Mitosis | 1 | 2002 | 68 |
Why?
| Mice, Nude | 1 | 2001 | 72 |
Why?
| Recombinant Proteins | 1 | 2004 | 290 |
Why?
| Family Practice | 1 | 2002 | 84 |
Why?
| Kinetics | 1 | 2004 | 349 |
Why?
| Transcriptional Activation | 1 | 2003 | 99 |
Why?
| Adolescent | 1 | 2010 | 891 |
Why?
| Polymorphism, Genetic | 1 | 2002 | 94 |
Why?
| Antineoplastic Agents | 1 | 2006 | 190 |
Why?
| Polymerase Chain Reaction | 1 | 2003 | 279 |
Why?
| Fibroblasts | 1 | 2003 | 179 |
Why?
| Physician's Practice Patterns | 1 | 2002 | 149 |
Why?
| Program Evaluation | 3 | 2003 | 115 |
Why?
| Infusions, Intravenous | 2 | 2006 | 87 |
Why?
| Drug Administration Schedule | 2 | 2006 | 191 |
Why?
| Survival Analysis | 2 | 2006 | 205 |
Why?
| Exercise | 2 | 2005 | 82 |
Why?
| Treatment Outcome | 3 | 2003 | 661 |
Why?
| Quality Assurance, Health Care | 2 | 2004 | 83 |
Why?
| Genetic Vectors | 2 | 2005 | 139 |
Why?
| Prognosis | 2 | 2006 | 388 |
Why?
| Prospective Studies | 2 | 2006 | 545 |
Why?
| Decision Making, Organizational | 1 | 2011 | 6 |
Why?
| Organizational Case Studies | 1 | 2011 | 13 |
Why?
| Qualitative Research | 1 | 2011 | 34 |
Why?
| Risk Assessment | 2 | 2005 | 324 |
Why?
| Focus Groups | 1 | 2011 | 38 |
Why?
| Lucanthone | 1 | 2010 | 1 |
Why?
| Radiation Tolerance | 1 | 2010 | 37 |
Why?
| Biomedical Engineering | 1 | 2009 | 11 |
Why?
| Cells, Cultured | 2 | 2003 | 447 |
Why?
| Motivation | 1 | 2011 | 85 |
Why?
| Indoles | 1 | 2010 | 69 |
Why?
| Micrococcal Nuclease | 1 | 2008 | 8 |
Why?
| RNA, Small Interfering | 1 | 2010 | 116 |
Why?
| DNA Damage | 1 | 2010 | 66 |
Why?
| Nucleosomes | 1 | 2008 | 7 |
Why?
| Cell Line, Tumor | 1 | 2010 | 208 |
Why?
| Selenium | 1 | 2007 | 15 |
Why?
| Ascorbic Acid | 1 | 2007 | 37 |
Why?
| Acetylcysteine | 1 | 2007 | 42 |
Why?
| Brain Neoplasms | 1 | 2010 | 116 |
Why?
| Great Britain | 1 | 2006 | 49 |
Why?
| Fish Oils | 1 | 2006 | 10 |
Why?
| Hematologic Diseases | 1 | 2006 | 23 |
Why?
| Administrative Personnel | 1 | 2006 | 19 |
Why?
| Calcium, Dietary | 1 | 2006 | 8 |
Why?
| Ovary | 1 | 2006 | 50 |
Why?
| Gene Expression | 1 | 2010 | 291 |
Why?
| Azo Compounds | 1 | 2005 | 15 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 109 |
Why?
| Disease-Free Survival | 1 | 2006 | 102 |
Why?
| Rats, Sprague-Dawley | 1 | 2009 | 257 |
Why?
| Sunlight | 1 | 2005 | 12 |
Why?
| Antigens, CD31 | 1 | 2005 | 17 |
Why?
| Judgment | 1 | 2005 | 10 |
Why?
| Magnesium | 1 | 2006 | 69 |
Why?
| Consensus | 1 | 2005 | 12 |
Why?
| Coloring Agents | 1 | 2005 | 42 |
Why?
| Protein Binding | 1 | 2008 | 256 |
Why?
| Comprehension | 1 | 2005 | 27 |
Why?
| Staining and Labeling | 1 | 2005 | 101 |
Why?
| Mice, Inbred Strains | 1 | 2005 | 118 |
Why?
| Hemoglobin A, Glycosylated | 1 | 2005 | 22 |
Why?
| Potassium | 1 | 2006 | 98 |
Why?
| Immunoenzyme Techniques | 1 | 2005 | 125 |
Why?
| Diet | 1 | 2006 | 87 |
Why?
| Tumor Necrosis Factors | 1 | 2004 | 13 |
Why?
| Green Fluorescent Proteins | 1 | 2005 | 105 |
Why?
| Double-Blind Method | 1 | 2007 | 274 |
Why?
| Cricetulus | 1 | 2004 | 39 |
Why?
| Tumor Markers, Biological | 1 | 2007 | 112 |
Why?
| Software | 1 | 2005 | 92 |
Why?
| Mice, Inbred C3H | 1 | 2004 | 86 |
Why?
| DNA, Bacterial | 1 | 2004 | 67 |
Why?
| CHO Cells | 1 | 2004 | 65 |
Why?
| Patient Compliance | 1 | 2005 | 113 |
Why?
| Ambulatory Care Facilities | 1 | 2003 | 27 |
Why?
| Pilot Projects | 1 | 2005 | 264 |
Why?
| Bone Morphogenetic Protein 7 | 1 | 2003 | 7 |
Why?
| Oxidative Stress | 1 | 2007 | 119 |
Why?
| Cricetinae | 1 | 2004 | 130 |
Why?
| Hedgehog Proteins | 1 | 2003 | 20 |
Why?
| Organizational Innovation | 1 | 2002 | 21 |
Why?
| Lipopolysaccharides | 1 | 2004 | 98 |
Why?
| Intervention Studies | 1 | 2002 | 30 |
Why?
| Analysis of Variance | 1 | 2005 | 339 |
Why?
| Cholesterol | 1 | 2003 | 86 |
Why?
| Knee Joint | 1 | 2003 | 30 |
Why?
| Community-Institutional Relations | 1 | 2002 | 13 |
Why?
| Femur | 1 | 2003 | 37 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 243 |
Why?
| Tissue Engineering | 1 | 2003 | 25 |
Why?
| Bone Morphogenetic Proteins | 1 | 2003 | 42 |
Why?
| Osteoarthritis | 1 | 2002 | 51 |
Why?
| Disease Models, Animal | 1 | 2005 | 349 |
Why?
| Rabbits | 1 | 2003 | 252 |
Why?
| Escherichia coli | 1 | 2004 | 143 |
Why?
| Rats | 1 | 2009 | 530 |
Why?
| Retrospective Studies | 1 | 2007 | 653 |
Why?
| Cytokines | 1 | 2004 | 207 |
Why?
| Questionnaires | 1 | 2005 | 360 |
Why?
| Follow-Up Studies | 1 | 2005 | 553 |
Why?
| Depressive Disorder | 1 | 2002 | 76 |
Why?
| Heart Failure | 1 | 2002 | 106 |
Why?
| Cardiovascular Diseases | 1 | 2002 | 127 |
Why?
|
|
Mason's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
